Abstract
The novel satiety factor nesfatin-1 and its precursor NUCB2 are the neuropeptides widely expressed in the central nervous system. Nesfatin-1/NUCB2 is also localized in peripheral tissues and regulates the glucose and energy metabolism on multiple processes. Nesfatin-1 potentiates both insulin release from pancreatic β-cells and insulin action in liver, contributing to energy storage. Furthermore, nesfatin-1/NUCB2 regulates adipocyte differentiation. The polymorphism of the NUCB2 gene is associated with obesity. Thus, nesfatin- 1/NUCB2 plays a role in integrating feeding, glucose homeostasis, and energy storage/expenditure. Dysfunction of expression, secretion and/or action of nesfatin-1/NUCB2 might be involved in the type 2 diabetes, obesity and metabolic syndrome. Nesfatin-1/NUCB2 and its regulatory processes may provide novel targets for treating associated diseases of the metabolic syndrome. Here, we review the by now published studies on nesfatin-1/NUCB2 localization and action in islets and discuss the physiological and pathophysiological roles of the nesfatin-1/NUCB2 in glucose and energy metabolism.
Keywords: Nesfatin-1, insulin release, adipogenesis, feeding.
Current Pharmaceutical Design
Title:Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Volume: 19 Issue: 39
Author(s): Masanori Nakata and Toshihiko Yada
Affiliation:
Keywords: Nesfatin-1, insulin release, adipogenesis, feeding.
Abstract: The novel satiety factor nesfatin-1 and its precursor NUCB2 are the neuropeptides widely expressed in the central nervous system. Nesfatin-1/NUCB2 is also localized in peripheral tissues and regulates the glucose and energy metabolism on multiple processes. Nesfatin-1 potentiates both insulin release from pancreatic β-cells and insulin action in liver, contributing to energy storage. Furthermore, nesfatin-1/NUCB2 regulates adipocyte differentiation. The polymorphism of the NUCB2 gene is associated with obesity. Thus, nesfatin- 1/NUCB2 plays a role in integrating feeding, glucose homeostasis, and energy storage/expenditure. Dysfunction of expression, secretion and/or action of nesfatin-1/NUCB2 might be involved in the type 2 diabetes, obesity and metabolic syndrome. Nesfatin-1/NUCB2 and its regulatory processes may provide novel targets for treating associated diseases of the metabolic syndrome. Here, we review the by now published studies on nesfatin-1/NUCB2 localization and action in islets and discuss the physiological and pathophysiological roles of the nesfatin-1/NUCB2 in glucose and energy metabolism.
Export Options
About this article
Cite this article as:
Nakata Masanori and Yada Toshihiko, Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127130112
DOI https://dx.doi.org/10.2174/138161281939131127130112 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction
Current Diabetes Reviews Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews Diabetes Mellitus as a Risk Factor for Cancer: Stress or Viral Etiology?
Infectious Disorders - Drug Targets Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Results of Controlled Clinical Trials Comparing “Guideline Exposed” and “Guideline Naive” Physicians in the Treatment of Depression, Hypertension,and Diabetes: What can be Learned?
Current Psychiatry Reviews “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation
Vascular Disease Prevention (Discontinued) Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Editorial: Paving the Way for Improved Antiplatelet Therapy
Current Pharmaceutical Design Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Ceruloplasmin, the Unique Multi-Copper Oxidase of Vertebrates
Protein & Peptide Letters Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology